REMARKS

Timely consideration of the application is respectfully requested in light of the amendments and the following remarks. Claims 55-111 are currently pending.

Claims 1-54 have been canceled without prejudice or disclaimer, and claims 55-111 have been added to more manifestly claim the invention. Support for the newly added claims is set forth in the Table below. Thus, no prohibited new matter has been added by the amendment.

Claim 55	Original claim 1 Pages 75-77-pharmaceutically acceptable carrier Page 56, line 25-isolated Page 8, lines 1-4-pathogen adhesin molecule and host adhesin molecule Page 3, lines 33-35, Page 20, line 33, through Page 21, line 5- specific binding Example 15 (especially page 62)-*in vitro* shear conditions Page 33, lines 28-31-therapeutically effective response
Claim 56	Original claim 1 Page 12, lines 15-21
Claim 57	Original claim 3
Claim 58	Original claim 4 Throughout the specification, see also page 2, lines 25-33- the pathogen adhesin molecule mimics an adhesion molecule of the host
Claim 59	Original claims 5, 6, 10, 13 and 16
Claim 60	Original claim 7
Claim 61	Original claims 11 and 12
Claim 62	Original claim 14

Claim 63	Original claim 2
Claim 64	Original claim 15
Claim 65	Original claim 18
Claim 66	Original claim 19
Claim 67	Original claim 20
Claim 68-72	Original claims 29-33 Page 13, lines 1-2, Page 31, lines 1-2, and other places in the specification-the recited classes of pathogens
Claim 73	Original claim 21
Claim 74	Original claim 22
Claim 75	Original claim 23
Claim 76	Original claim 24
Claim 77	Original claim 25
Claim 78	Original claim 26
Claim 79	Original claim 27
Claim 80	Original claim 28
Claim 81	Original claim 29
Claim 82	Original claim 30
Claim 83	Original claim 31
Claim 84	Original claim 32
Claim 85	Original claim 33
Claim 86	Original claim 1 Page 33, lines 18-32-description of the cited delivery vectors
Claim 87	Original claim 1 Page 77, lines 14-29-description of the cited vectors

Claim 88	Original claim 1 Page 77, lines 14-29-description of the cited vectors
Claim 89	Original claim 1 Pages 75-77-pharmaceutically acceptable carrier Page 56, line 25-isolated Page 8, lines 1-4-pathogen adhesin molecule and host adhesin molecule Page 3, lines 33-35, Page 20, line 33, through Page 21, line 5-specific binding Example 15 (especially page 62)-*in vitro* shear conditions Page 33, lines 28-31-therapeutically effective response
Claim 90	Original claim 1 Page 32, lines 10-12; Page 34, lines 5-12, Page 48, lines 6-8-mimetics Pages 75-77-pharmaceutically acceptable carrier Page 56, line 25-isolated Page 8, lines 1-4-pathogen adhesin molecule and host adhesin molecule Page 3, lines 33-35, Page 20, line 33, through Page 21, line 5-specific binding Page 33, lines 28-31-therapeutically effective response
Claim 91	Original claim 50 Page 33, lines 28-31-therapeutically effective response
Claim 92	Original claim 51
Claim 93	Original claim 52
Claim 94	Original claim 53 Page 32, lines 10-12; Page 34, lines 5-12, Page 48, lines 6-8-

	mimetics
Claim 95	Original claim 34 Page 8, lines 1-4-pathogen adhesin molecule and host adhesin molecule Page 3, lines 33-35, Page 20, line 33, through Page 21, line 5-specific binding Page 33, lines 28-31-therapeutically effective response
Claim 96	Original claim 34
Claim 97	Original claims 34 and 36
Claim 98	Original claim 35 Page 32, lines 10-12; Page 34, lines 5-12, Page 48, lines 6-8-mimetics Page 8, lines 1-4-pathogen adhesin molecule and host adhesin molecule Page 3, lines 33-35, Page 20, line 33, through Page 21, line 5-specific binding Example 15 (especially page 62)-*in vitro* shear conditions
Claim 99	Original claims 37 and 15 Page 8, lines 1-4-pathogen adhesin molecule and host adhesin molecule Page 3, lines 33-35, Page 20, line 33, through Page 21, line 5-specific binding Example 15 (especially page 62)-*in vitro* shear conditions
Claim 100	Original claim 38 Pages 75-77-pharmaceutically acceptable carrier Page 56, line 25-isolated Page 8, lines 1-4-pathogen adhesin molecule and host adhesin molecule Page 3, lines 33-35, Page 20, line 33, through Page 21, line 5-

	specific binding Example 15 (especially page 62)-*in vitro* shear conditions Page 33, lines 28-31-therapeutically effective response
Claim 101	Original claim 38 and others Page 17, lines 1-6, page 30, lines 20-25-inhibition of the recited events
Claim 102	Original claims 38 and 39
Claim 103	Original claims 38 and 40
Claim 104	Original claims 38 and 41
Claim 105	Original claims 38 and 42
Claim 106	Original claims 38, 5, 6, 10, 13 and 16
Claim 107	Original claims 38 and 7
Claim 108	Original claims 38, 11 and 12
Claim 109	Original claims 38 and 14
Claim 110	Original claims 38 and 18
Claim 111	Original claims 38 and 19

I. Summary of the Restriction Requirement and Response Thereto

The restriction requirement of paper # 13 restricted original claims 1-55 into three groups.

I. Original claims 1-49, which correspond to new claims 55-90 and 95-111, drawn to vaccines comprising attachment molecules.

II. Original claims 50-53, which correspond to new claims 91-94, drawn to a method of obtaining a vaccine comprising isolating a PAM and developing antibodies thereto.

III. Original claim 54, which does not correspond to any of the newly presented claims, drawn to a method of obtaining a vaccine comprising isolating a molecule which mimics a pathogen adhesin molecule and incorporating said molecule into a vaccine.

In addition, the Response to the Restriction Requirement elected the following species:

A) (1)-drawn to attachment molecules comprising proteins and glycoproteins

B) (2)-drawn to endothelial cells

C) (6)-drawn to mannose

D) (1)-drawn to selectin or integrin

E)-Not applicable

F) (16)-ICAM-1

G) (21)-Candida

Thus, through this supplemental amendments, claims 55-110 are pending, claims 55-90 and 95-111 correspond to elected group I, and claims 91-94 stand withdrawn from consideration.

II. Conclusion

Should the Examiner feel that there are any issues outstanding after consideration of this Supplemental Amendment, the Examiner is invited to contact the Applicants' undersigned representative to expedite prosecution.

In the unlikely event that the transmittal letter submitted herewith is separated from this document, and except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application, including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted,

MORGAN, LEWIS & BOCKIUS LLP

Date: May 17, 2001

By: 

Lora M. Green
Reg. No. 43,541

CUSTOMER NO. 009629
MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, N.W.
Washington, D.C. 20036-5869
Tel. (202) 467-7000
Fax (202) 467-7258